Keros Therapeutics (NASDAQ: KROS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -1.010 | -0.1500 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Keros Therapeutics (NASDAQ: KROS) through any online brokerage.
Other companies in Keros Therapeutics’s space includes: Avidity Biosciences (NASDAQ:RNA), TG Therapeutics (NASDAQ:TGTX), Sangamo Therapeutics (NASDAQ:SGMO), PMV Pharma (NASDAQ:PMVP) and Kiniksa Pharmaceuticals (NASDAQ:KNSA).
The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by SVB Leerink on Tuesday, December 8, 2020. The analyst firm set a price target for 80.00 expecting KROS to rise to within 12 months (a possible 184.80% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Keros Therapeutics (NASDAQ: KROS) is $28.09 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Keros Therapeutics.
Keros Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Keros Therapeutics.
Keros Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.